Heron Therapeutics, Inc. (HRTX) P/E Ratio History
Historical price-to-earnings valuation from 1997 to 2006
Loading P/E history...
HRTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Heron Therapeutics, Inc. (HRTX) trades at a price-to-earnings ratio of -10.1x, with a stock price of $1.21 and trailing twelve-month earnings per share of $-0.12.
The current P/E is 117% below its 5-year average of 60.9x. Over the past five years, HRTX's P/E has ranged from a low of 1.0x to a high of 495.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, HRTX trades at a 145% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, HRTX trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HRTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HRTX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $911M | 144.7 | - | +107% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $2B | 11.4 | - | +8% | |
| $90B | 28.6 | 0.73 | +15% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
HRTX Historical P/E Data (1997–2006)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2006 Q2 | Fri Jun 30 2006 00:00:00 GM | $140.00 | $32.53 | 4.3x | -93% |
| FY2006 Q1 | Fri Mar 31 2006 00:00:00 GM | $160.00 | $38.94 | 4.1x | -93% |
| FY2001 Q2 | Sat Jun 30 2001 00:00:00 GM | $240.00 | $150.94 | 1.6x | -97% |
| FY2001 Q1 | Sat Mar 31 2001 00:00:00 GM | $165.00 | $153.15 | 1.1x | -98% |
| FY2000 Q4 | Sun Dec 31 2000 00:00:00 GM | $190.00 | $160.79 | 1.2x | -98% |
| FY2000 Q3 | Sat Sep 30 2000 00:00:00 GM | $170.00 | $172.65 | 1.0x | -98% |
| FY2000 Q2 | Fri Jun 30 2000 00:00:00 GM | $302.50 | $15.85 | 19.1x | -69% |
| FY2000 Q1 | Fri Mar 31 2000 00:00:00 GM | $400.00 | $20.27 | 19.7x | -68% |
| FY1999 Q4 | Fri Dec 31 1999 00:00:00 GM | $275.00 | $23.47 | 11.7x | -81% |
| FY1999 Q3 | $330.00 | $22.29 | 14.8x | -76% | |
| FY1999 Q2 | Wed Jun 30 1999 00:00:00 GM | $560.00 | $22.29 | 25.1x | -59% |
| FY1999 Q1 | Wed Mar 31 1999 00:00:00 GM | $350.00 | $23.58 | 14.8x | -76% |
Average P/E for displayed period: 60.9x
See HRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHRTX — Frequently Asked Questions
Quick answers to the most common questions about buying HRTX stock.
Is HRTX stock overvalued or undervalued?
HRTX trades at -10.1x P/E, below its 5-year average of 60.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does HRTX's valuation compare to peers?
Heron Therapeutics, Inc. P/E of -10.1x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is HRTX's PEG ratio?
HRTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1997-2006.